RE:RE:RE:RE:New Press Release - Theratechnologies Announces Path to Resume TH1902 Clinical DevelopmentThere was no time when they weren't considering patient selection. Choosing to take all-comers IS making a choice on patient selection, we were told that was in-line with what the FDA wanted and there is just no way the FDA would allow a trial to start if it hadn't considered patient selection. Your problem is you have never understood what was the intention of taking all-comers so you just dismiss it as though it was an unthinking decision. As an example we don't know what type of analyses they are doing now to get them back on track but having SORT+ and SORT- patients to look at might be contributing to that understanding. If this hadn't paused, failed to get responders and had enrolled enough to get to the end of an extended phase 1 then having patients of all different SORT levels would have informed that analysis too. That I think was the reason for all-comer, it wasn't an unconsidered choice.